Severity
Moderate
FDA Drug recall · Reported March 20, 2013
CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.
Rx South LLC DBA Rx3 Pharmacy recalled Medi-bolic Booster Injectable (methionine 8.3 mg/mL, choline chloride 16.6 mg/mL, inosito… - a moderate-severity action.
Medi-bolic Booster Injectable (methionine 8.3 mg/mL, choline chloride 16.6 mg/mL, inosito… was recalled by Rx South LLC DBA Rx3 Pharmacy in March 20, 2013. Reason: CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.. Check the official notice for the remedy. Verify recall #D-191-2013 with the FDA Drug before acting.
The recall
Rx South LLC DBA Rx3 Pharmacy issued this moderate-severity FDA Drug recall-CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures..
Sourced from official FDA Drug enforcement records. Verify recall #D-191-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-191-2013) was formally reported on March 20, 2013, with the manufacturer initiating the action on January 22, 2013. It is classified under Moderate severity (Class II), with a current status of Terminated. Rx South LLC DBA Rx3 Pharmacy is listed as the recalling firm, operating out of Chester, VA. Federal records list the affected scope as 126 vials.
The documented reason for this recall is: CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
126 vials
Related Recalls
6
5 from same agency
Medi-bolic Booster Injectable (methionine 8.3 mg/mL, choline chloride 16.6 mg/mL, inositol 16.6 mg/mL, cyanocobalamin USP [Vit B12] 0.33 mg/mL, chromium chloride 2.6 mg/mL), 30 mL multi-dose vials, Rx3 Compounding Pharmacy, 12230 Ironbridge Rd., Suite C, Chester, VA 23831.
CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-191-2013 |
| Date reported | March 20, 2013 |
| Date initiated | January 22, 2013 |
| Recalling firm | Rx South LLC DBA Rx3 Pharmacy |
| Firm location | Chester, VA |
| Affected scope | 126 vials |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 20, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.